Click on image to view larger version.

Figure 1 Meta Analysis of nine trials of glycoprotein IIb/IIIa antagonists in patients with unstable coronary syndromes. Shown are the 95% confidence intervals for the relative risk ratio of adverse events, including myocardial infarction, recurrent ischemia, and death in patients receiving a glycoprotein IIb/IIIa antagonist in addition to standard therapy with aspirin and heparin. The overall relative risk ratio was 0.79 (p = 0.019). Solid circles = lower 95% C.I. for RR; open circles = relative risk; solid triangles = upper 95% C.I. for RR.